Skip To Main Content
Anton Barnett on Muck Rack

Anton Barnett

As seen in: medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anton

Contact Anton, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial

|
By Mark A. Faghy, Jade Chynoweth, Anton Barnett
| medRxiv
Abstract Objective: Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC.
Open in Who Shared Issue with article?

Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study

|
By Lexy Sorrell, Valentina Leta, Anton Barnett, Kara Stevens Verified
| paperity.org
PLOS ONE, Jul 2023 Background Parkinson’s disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson’s disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.
Open in Who Shared Issue with article?
See all 2 articles